Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Navigating mCRC: A Closer Look at Biomarker Testing



ReachMD Healthcare Image

Explore how we can use biomarker testing in metastatic colorectal cancer care to personalize treatment options and potentially improve survival rates.

  • Sponsored by

  • Overview

    Consistent biomarker testing early in the diagnosis is the key to giving our patients their best chance in their fight against metastatic colorectal cancer (mCRC). Unfortunately, this type of testing has been challenging to adopt universally because of multiple barriers.1 Tune in to hear Dr. Charles Turck discuss the role of biomarker testing in mCRC care and how we can overcome obstacles with Dr. Kristen Ciombor, Associate Professor of Medicine at Vanderbilt-Ingram Center in Nashville, Tennessee.

    The healthcare providers featured in this episode have been paid by Pfizer for their time.


    1.  Siegel RL, Wagle NS, Cercek A, Smith RA, Jemal A. Colorectal cancer statistics, 2023 [published online ahead of print, 2023 Mar 1]. CA Cancer J Clin. 2023;10.3322/caac.21772. doi:10.3322/caac.21772

    Continuing medical education credits are not available for this program.
    © 2023 Pfizer Inc. All rights reserved. PP-UNP-USA-2088 June 2023

Schedule28 Sep 2023